Laser-assisted drug delivery: Enhanced response to ingenol mebutate after ablative fractional laser treatment - 13/01/15
Doi : 10.1016/j.jaad.2014.09.055
Stephan Alexander Braun, MD a, ⁎ 
, Peter Hevezi, PhD b, Bernhard Homey, MD a, Peter Arne Gerber, MD, DALM a
, Peter Hevezi, PhD b, Bernhard Homey, MD a, Peter Arne Gerber, MD, DALM a a Department of Dermatology, Medical Faculty, University of Düsseldorf, Germany
b Department of Physiology and Biophysics, University of California, Irvine, California
∗Correspondence to: Stephan Alexander Braun, MD, and Peter Arne Gerber, MD, DALM, Dept of Dermatology, Medical Faculty University of Düsseldorf, Moorenstr 5, 40225 Düsseldorf, Germany
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: S. A. Braun and P. A. Gerber have received research funding from LEO Pharma. B. Homey is a consultant for Leo Pharma. P. A. Gerber has received lecture fees from Asclepion Laser Technologies. P. Hevezi has no conflicts of interest. |
© 2014
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 72 - N° 2
P. 364-365 - février 2015 Retour au numéro
Article précédent
- Alitretinoin and Darier disease: “All that glisters is not gold”
- Riccardo Balestri, Annalisa Patrizi, Federico Bardazzi
- Reply to: “Laser assisted drug delivery: Enhanced response to ingenol mebutate after ablative fractional laser treatment”
- Giuseppe Micali, Francesco Lacarrubba, Maria Rita Nasca
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?